University of California San Francisco
Give to UCSFA new study by UCSF researchers points to changes in intestinal bacteria as a possible explanation for why successfully treated HIV patients nonetheless experience life-shortening chronic diseases.
Two veteran UCSF doctors who have been battling the AIDS epidemic for decades retraced past efforts and described their ongoing quest for a cure for HIV in the Academic Senate’s Third Annual Faculty Research Lecture.
UC San Francisco, a frequent high-performing team at AIDS Walk San Francisco, will again for the gold – the honor given to the top fundraising organizations participating in the annual event.
<p>Community intervention with free mobile HIV testing and counseling, same-day results and post-test support led to a 14 percent reduction in new HIV infections in targeted communities in Sub-Saharan Africa, according to results of a large randomized, controlled trial.</p>
<p>UCSF and the Gladstone Institutes will observe World AIDS Day on December 3 with a symposium featuring emerging investigators working to combat the disease.</p>
<p>Global health pioneer Paul Farmer, MD, PhD, addressed a packed UCSF auditorium in a special lecture about a community-based health care model that his nonprofit organization, Partners In Health, has brought to some of the world's most impoverished countries, including Haiti and Rwanda.</p>
<p>The National Institutes of Health has awarded more than $15 million over the next five years to the UCSF-Gladstone Center for AIDS Research (CFAR) to continue its pioneering translational AIDS research.</p>
Starting HIV-infected patients on antiretroviral therapy reduces food insecurity and improves physical health, thereby contributing to the disruption of a lethal syndemic, UCSF and Massachusetts General Hospital researchers have found in a study focused on sub-Saharan Africa.
Scientists at the UCSF-affiliated Gladstone Institutes have devised a method to track HIV inside individual cells — an important development for understanding “HIV latency" when the virus goes dormant after the patient begins antiretroviral treatment.
New research from an international team of HIV/AIDS experts has reaffirmed the effectiveness of Truvada — the first and only medication approved by the FDA for HIV prevention.